vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and GLOBAL INDUSTRIAL Co (GIC). Click either name above to swap in a different company.
GLOBAL INDUSTRIAL Co is the larger business by last-quarter revenue ($345.6M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 4.2%, a 6.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 14.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $19.2M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 3.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Global Industrial Company is a Port Washington, New York–based company providing industrial and MRO products through a system of branded e-Commerce websites and relationship marketers in North America. The primary brand is Global Industrial.
ANIP vs GIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $345.6M |
| Net Profit | $27.5M | $14.6M |
| Gross Margin | — | 34.5% |
| Operating Margin | 14.1% | 5.7% |
| Net Margin | 11.1% | 4.2% |
| Revenue YoY | 29.6% | 14.3% |
| Net Profit YoY | 367.5% | 36.4% |
| EPS (diluted) | $1.14 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $345.6M | ||
| Q3 25 | $227.8M | $353.6M | ||
| Q2 25 | $211.4M | $358.9M | ||
| Q1 25 | $197.1M | $321.0M | ||
| Q4 24 | $190.6M | $302.3M | ||
| Q3 24 | $148.3M | $342.4M | ||
| Q2 24 | $138.0M | $347.8M | ||
| Q1 24 | $137.4M | $323.4M |
| Q4 25 | $27.5M | $14.6M | ||
| Q3 25 | $26.6M | $18.8M | ||
| Q2 25 | $8.5M | $25.1M | ||
| Q1 25 | $15.7M | $13.6M | ||
| Q4 24 | $-10.3M | $10.7M | ||
| Q3 24 | $-24.2M | $16.8M | ||
| Q2 24 | $-2.3M | $20.3M | ||
| Q1 24 | $18.2M | $13.2M |
| Q4 25 | — | 34.5% | ||
| Q3 25 | — | 35.6% | ||
| Q2 25 | — | 37.1% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 33.8% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 35.2% | ||
| Q1 24 | — | 34.3% |
| Q4 25 | 14.1% | 5.7% | ||
| Q3 25 | 15.9% | 7.4% | ||
| Q2 25 | 6.6% | 9.3% | ||
| Q1 25 | 13.3% | 5.7% | ||
| Q4 24 | -2.3% | 4.8% | ||
| Q3 24 | -13.8% | 6.5% | ||
| Q2 24 | 3.7% | 7.6% | ||
| Q1 24 | 14.8% | 5.4% |
| Q4 25 | 11.1% | 4.2% | ||
| Q3 25 | 11.7% | 5.3% | ||
| Q2 25 | 4.0% | 7.0% | ||
| Q1 25 | 8.0% | 4.2% | ||
| Q4 24 | -5.4% | 3.5% | ||
| Q3 24 | -16.3% | 4.9% | ||
| Q2 24 | -1.7% | 5.8% | ||
| Q1 24 | 13.2% | 4.1% |
| Q4 25 | $1.14 | $0.37 | ||
| Q3 25 | $1.13 | $0.48 | ||
| Q2 25 | $0.36 | $0.65 | ||
| Q1 25 | $0.69 | $0.35 | ||
| Q4 24 | $-0.45 | $0.28 | ||
| Q3 24 | $-1.27 | $0.44 | ||
| Q2 24 | $-0.14 | $0.52 | ||
| Q1 24 | $0.82 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $67.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $313.2M |
| Total Assets | $1.4B | $580.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $67.5M | ||
| Q3 25 | $262.6M | $67.2M | ||
| Q2 25 | $217.8M | $55.1M | ||
| Q1 25 | $149.8M | $39.0M | ||
| Q4 24 | $144.9M | $44.6M | ||
| Q3 24 | $145.0M | $38.9M | ||
| Q2 24 | $240.1M | $38.8M | ||
| Q1 24 | $228.6M | $29.9M |
| Q4 25 | $540.7M | $313.2M | ||
| Q3 25 | $505.8M | $316.0M | ||
| Q2 25 | $436.8M | $305.2M | ||
| Q1 25 | $418.6M | $287.9M | ||
| Q4 24 | $403.7M | $281.1M | ||
| Q3 24 | $405.9M | $279.2M | ||
| Q2 24 | $455.8M | $270.4M | ||
| Q1 24 | $452.0M | $260.2M |
| Q4 25 | $1.4B | $580.8M | ||
| Q3 25 | $1.4B | $602.5M | ||
| Q2 25 | $1.3B | $586.5M | ||
| Q1 25 | $1.3B | $536.7M | ||
| Q4 24 | $1.3B | $520.7M | ||
| Q3 24 | $1.3B | $531.6M | ||
| Q2 24 | $920.8M | $542.5M | ||
| Q1 24 | $914.5M | $517.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $20.0M |
| Free Cash FlowOCF − Capex | $29.1M | $19.2M |
| FCF MarginFCF / Revenue | 11.8% | 5.6% |
| Capex IntensityCapex / Revenue | 0.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.37× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $74.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $20.0M | ||
| Q3 25 | $44.1M | $22.7M | ||
| Q2 25 | $75.8M | $31.7M | ||
| Q1 25 | $35.0M | $3.4M | ||
| Q4 24 | $15.9M | $15.9M | ||
| Q3 24 | $12.5M | $9.6M | ||
| Q2 24 | $17.4M | $18.8M | ||
| Q1 24 | $18.3M | $6.4M |
| Q4 25 | $29.1M | $19.2M | ||
| Q3 25 | $38.0M | $22.0M | ||
| Q2 25 | $71.8M | $30.3M | ||
| Q1 25 | $32.5M | $3.2M | ||
| Q4 24 | $13.5M | $15.2M | ||
| Q3 24 | $7.7M | $8.7M | ||
| Q2 24 | $13.0M | $17.9M | ||
| Q1 24 | $13.7M | $5.1M |
| Q4 25 | 11.8% | 5.6% | ||
| Q3 25 | 16.7% | 6.2% | ||
| Q2 25 | 34.0% | 8.4% | ||
| Q1 25 | 16.5% | 1.0% | ||
| Q4 24 | 7.1% | 5.0% | ||
| Q3 24 | 5.2% | 2.5% | ||
| Q2 24 | 9.4% | 5.1% | ||
| Q1 24 | 10.0% | 1.6% |
| Q4 25 | 0.5% | 0.2% | ||
| Q3 25 | 2.7% | 0.2% | ||
| Q2 25 | 1.9% | 0.4% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 0.2% | ||
| Q3 24 | 3.2% | 0.3% | ||
| Q2 24 | 3.2% | 0.3% | ||
| Q1 24 | 3.3% | 0.4% |
| Q4 25 | 1.10× | 1.37× | ||
| Q3 25 | 1.66× | 1.21× | ||
| Q2 25 | 8.87× | 1.26× | ||
| Q1 25 | 2.23× | 0.25× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | 1.00× | 0.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GIC
Segment breakdown not available.
